Elsevier

Drug Resistance Updates

Volume 2, Issue 5, October 1999, Pages 307-318
Drug Resistance Updates

Regular Article
Topoisomerase I inhibitors: selectivity and cellular resistance

https://doi.org/10.1054/drup.1999.0102Get rights and content

Abstract

Topoisomerase I (top1) inhibitors (camptothecins and other structurally diverse compounds) are effective and promising anticancer agents. Determinants of selectivity toward cancer cells and resistance are multifactorial. These factors can be separated in three groups. The first is related to alterations in drug distribution and metabolism. The second group includes both quantitative and qualitative (mutations) differences in top I. The third group includes resistance and sensitivity factors downstream from the cleavage complexes. They include DNA repair, cell cycle checkpoints and apoptosis, and are probably key to the relative selectivity of camptothecins toward cancer cells and to clinical resistance.

References (120)

  • J-Y. Chang et al.

    Characterization of camptothecin-resistant chinese hamster lung cells

    Biochem Pharmacol

    (1992)
  • I. Madelaine et al.

    Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation

    Biochem Pharmacol

    (1993)
  • M. Oguro et al.

    Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines

    Biomed Pharmacother

    (1990)
  • P. Pourquier et al.

    Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I

    J Biol Chem

    (1997)
  • P. Pourquier et al.

    Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects

    J Biol Chem

    (1997)
  • P. Pourquier et al.

    Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1, N6-ethenoadenine

    J Biol Chem

    (1998)
  • S.D. Desai et al.

    Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

    J Biol Chem

    (1997)
  • S. Sastry et al.

    Mechanisms for the processing of a prozen topoisomerase-DNA conjugate by human cell-free extracts

    J Biol Chem

    (1998)
  • K. Samejima et al.

    Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis

    J Biol Chem

    (1999)
  • J.C. Wang

    DNA topoisomerases

    Annu Rev Biochem

    (1996)
  • Y. Pommier et al.

    Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

    Biochim Biophys Acta

    (1998)
  • A.Y. Chen et al.

    DNA Topoisomerases: essential enzymes and lethal targets

    Annu Rev Pharmacol Toxicol

    (1994)
  • Y. Pommier et al.

    Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

    Cancer Invest

    (1994)
  • Y. Pommier et al.

    DNA topoisomerase I inhibitors and multidrug resistance

  • P. Pourquier et al.

    Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro

    Nucleic Acids Res

    (1999)
  • J. Wu et al.

    Processing of topoisomerase I cleavable complexes into DNA damage by transcription

    Nucleic Acids Res

    (1997)
  • Y. Pommier

    Topoisomerase inhibitors: Why develop new ones

    Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs

    (1999)
  • B. Poddevin et al.

    Dual topoisomerase I and II inhibition by intoplicine (RP-60475) a new antitumor agent in early clinical trials

    Mol Pharmacol

    (1993)
  • C. Bailly et al.

    DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin

    Biochemistry

    (1997)
  • D. Strumberg et al.

    Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons

    J Med Chem

    (1999)
  • C. Bailly et al.

    Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents

    Cancer Res

    (1999)
  • A. Tanizawa et al.

    Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

    J Natl Cancer Inst

    (1994)
  • A. Tanizawa et al.

    Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives

    Biochemistry

    (1995)
  • P.M. Potter et al.

    Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme

    Cancer Res

    (1998)
  • C.L. Morton et al.

    The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase

    Cancer Res

    (1999)
  • M.C. Haaz et al.

    The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms

    Naunyn Schmiedebergs Arch Pharmacol

    (1997)
  • S. Niimi et al.

    Mechanism of cross-resistane to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin

    Cancer Res

    (1992)
  • F. Kanzawa et al.

    Establishement of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

    Cancer Res

    (1990)
  • S. Nagai et al.

    Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin)

    J Surg Oncol

    (1995)
  • N. Saijo et al.

    7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials

    Cancer Chemother Pharmacol

    (1994)
  • M.K. Danks et al.

    Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11

    Cancer Res

    (1998)
  • L.P. Rivory et al.

    Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients

    Cancer Res

    (1996)
  • H. Rosing et al.

    O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyltopotecan

    Anticancer Drugs

    (1998)
  • E. Gupta et al.

    Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

    Cancer Res

    (1994)
  • L.P. Rivory et al.

    Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

    Cancer Chemother Pharmacol

    (1995)
  • L. Iyer et al.

    Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

    J Clin Invest

    (1998)
  • L. Lyer et al.

    Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

    J Clin Invest

    (1998)
  • T. Takahashi et al.

    The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro

    Jpn J Cancer Res

    (1997)
  • C.B. Hendricks et al.

    Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue

    Cancer Res

    (1992)
  • S.V. Ambudkar et al.

    Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis

    Proc Natl Acad Sci USA

    (1992)
  • Cited by (171)

    View all citing articles on Scopus
    View full text